CobanHGermaineSDimaandalI, et al. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population. Mult Scler Relat Disord2021; 53: 103021.
2.
AfzalMCRommeJGynthersenM, et al. Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report. Mult Scler J2024.
3.
HaberliNCobanHPadamC, et al. Babesia microti infection in a patient with multiple sclerosis treated with ocrelizumab. Mult Scler Relat Disord2021; 48: 102731.
4.
TorinaABlandaVVillariS, et al. Immune response to tick-borne hemoparasites: Host adaptive immune response mechanisms as potential targets for therapies and vaccines. Int J Mol Sci2020; 21(22): 8813.
5.
KapadiaRKStaplesJEGillCM, et al. Severe arboviral neuroinvasive disease in patients on rituximab therapy: A review. Clin Infect Dis2023; 76(6): 1142–1148.
